IL17A and rheumatoid arthritis: More importantly, we observed no reductions in circulating Th22, Th17, IL-22+Th17 or plasma levels of IL-22, IL-17, or IFN-γ in non-responders, further supporting the significance of these cells and cytokines in determining response to MTX+LEF treatment in RA.